Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Shares Outstanding (2016 - 2025)

Marimed (MRMD) has disclosed Shares Outstanding for 15 consecutive years, with $394.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 3.53% to $394.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $394.5 million, a 3.53% increase, with the full-year FY2024 number at $381.5 million, up 1.69% from a year prior.
  • Shares Outstanding was $394.5 million for Q3 2025 at Marimed, up from $392.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $394.5 million in Q3 2025 to a low of $70000.0 in Q4 2022.
  • A 5-year average of $317.9 million and a median of $348.1 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: crashed 100.0% in 2021, then surged 7471845.59% in 2024.
  • Marimed's Shares Outstanding stood at $331.5 million in 2021, then crashed by 99.98% to $70000.0 in 2022, then surged by 535794.79% to $375.1 million in 2023, then increased by 1.69% to $381.5 million in 2024, then grew by 3.4% to $394.5 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Shares Outstanding are $394.5 million (Q3 2025), $392.0 million (Q2 2025), and $388.7 million (Q1 2025).